{"id":"sp-8203","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, SP-8203 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"SP-8203 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:37.789Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06660719","phase":"PHASE3","title":"Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care","status":"RECRUITING","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2025-02-14","conditions":"Ischemic Stroke","enrollment":852},{"nctId":"NCT04479449","phase":"PHASE2","title":"Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2019-03-18","conditions":"Ischemic Stroke","enrollment":178},{"nctId":"NCT01757795","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of SP-8203","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2013-12-23","conditions":"Ischemic Stroke","enrollment":72},{"nctId":"NCT02787278","phase":"PHASE2","title":"Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2016-06-05","conditions":"Ischemic Stroke","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SP8203HCL","Otaplimastat (SP-8203)"],"phase":"phase_3","status":"active","brandName":"SP-8203","genericName":"SP-8203","companyName":"Shin Poong Pharmaceutical Co. Ltd.","companyId":"shin-poong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SP-8203 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}